CancerConnect

The U.S. Food and Drug Administration (FDA) has approved tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and pertuzumab (Perjeta) for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. The approval, announced October 7, 2026, provides a new option to help keep cancer fr...

The FDA has approved new first-line treatment options that include zanidatamab-hrii
(Ziihera) for certain adults with HER2-positive advanced stomach, gastroesophageal
junction (GEJ), or esophageal adenocarcinoma. The approvals may offer a new option
for people whose cancer cannot be removed with surgery or has spread to other parts
of the body.fda
Wha...